secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0001655759-25-000066
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Phase 1 data: ARV-102 achieves >50% central and >90% peripheral LRRK2 degradation
--------------------------------------------------------------------------------

- ARV-102 well tolerated in healthy volunteers; no serious adverse events in SAD (completed) or MAD (ongoing) cohorts.
- At single dose ≥60 mg and repeated ≥20 mg: >90% LRRK2 reduction in PBMCs and >50% in CSF.
- Median Tmax 6h, terminal half-life 73h; CSF exposure dose-dependent across SAD and MAD.
- Phase 1 trial in Parkinson's disease patients initiated Q4 2024; initial patient data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000066/0001655759-25-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000066/arvn-20250404.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer